Mustang Bio (MBIO) Non-Current Assets (2017 - 2024)
Mustang Bio (MBIO) posted quarterly Non-Current Assets of $702000.0 for Q4 2024, down 89.02% year-over-year from $6.4 million in Q1 2024, and down 38.31% quarter-over-quarter from $1.1 million in Q3 2024.
Mustang Bio (MBIO) Non-Current Assets (2017 - 2024) Analysis & Trends
Mustang Bio (MBIO) has reported Non-Current Assets for 8 consecutive years, with $702000.0 the latest figure, recorded in Q4 2024.
- In Q4 2024, Non-Current Assets fell 89.02% year-over-year to $702000.0; the TTM figure through Sep 2025 stood at $702000.0 (down 95.02% YoY), while the FY2024 annual figure was $702000.0, down 89.02% from the prior year.
- Non-Current Assets eased to $702000.0 in Q4 2024 per MBIO's latest filing, from $1.1 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $14.4 million in Q3 2022 and bottomed at $702000.0 in Q4 2024.
- Historically, Non-Current Assets has averaged $9.3 million across 5 years, with a median of $10.7 million in 2020.
- Annual changes were most pronounced in 2021 — Non-Current Assets increased 29.89% — and 2024, when it tumbled 89.02%.
- Mustang Bio's Non-Current Assets stood at $10.4 million in 2020, then climbed by 29.89% to $13.5 million in 2021, then increased by 0.79% to $13.6 million in 2022, then plunged by 52.87% to $6.4 million in 2023, then sank by 89.02% to $702000.0 in 2024.
- Business Quant data shows MBIO's Non-Current Assets at $702000.0 in Q4 2024, $1.1 million in Q3 2024, and $1.2 million in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.84 Bn | 131.99 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 86.48 Bn | 78.49 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 65.47 Bn | 60.29 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 60.15 Bn | 55.01 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 42.22 Bn | 37.12 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.54 Bn | 10.14 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.22 Bn | 26.38 Bn | - | 18.06 Bn |
| 10 | Mustang Bio | 3.86 Mn | 3.86 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 702,000.00 |
| Sep 30, 2024 | 1.14 Mn |
| Jun 30, 2024 | 1.20 Mn |
| Mar 31, 2024 | 5.35 Mn |
| Dec 31, 2023 | 6.40 Mn |
| Sep 30, 2023 | 6.98 Mn |
| Jun 30, 2023 | 6.51 Mn |
| Mar 31, 2023 | 12.48 Mn |
| Dec 31, 2022 | 13.57 Mn |
| Sep 30, 2022 | 14.39 Mn |
| Jun 30, 2022 | 12.53 Mn |
| Mar 31, 2022 | 12.81 Mn |
| Dec 31, 2021 | 13.46 Mn |
| Sep 30, 2021 | 12.76 Mn |
| Jun 30, 2021 | 11.87 Mn |
| Mar 31, 2021 | 10.85 Mn |
| Dec 31, 2020 | 10.37 Mn |
| Sep 30, 2020 | 10.44 Mn |
| Jun 30, 2020 | 10.56 Mn |
| Mar 31, 2020 | 10.86 Mn |